JP2017526625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526625A5 JP2017526625A5 JP2016574456A JP2016574456A JP2017526625A5 JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5 JP 2016574456 A JP2016574456 A JP 2016574456A JP 2016574456 A JP2016574456 A JP 2016574456A JP 2017526625 A5 JP2017526625 A5 JP 2017526625A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- region
- polypeptide
- protein dimer
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411506.7A GB201411506D0 (en) | 2014-06-27 | 2014-06-27 | Modified latency associated protein construct |
| GB1411506.7 | 2014-06-27 | ||
| PCT/GB2015/051877 WO2015198072A1 (en) | 2014-06-27 | 2015-06-26 | Modified latency associated protein construct |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526625A JP2017526625A (ja) | 2017-09-14 |
| JP2017526625A5 true JP2017526625A5 (enExample) | 2018-06-28 |
| JP6687548B2 JP6687548B2 (ja) | 2020-04-22 |
Family
ID=51410274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574456A Expired - Fee Related JP6687548B2 (ja) | 2014-06-27 | 2015-06-26 | 変性された潜在関連蛋白質構成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10435451B2 (enExample) |
| EP (1) | EP3160992B1 (enExample) |
| JP (1) | JP6687548B2 (enExample) |
| GB (1) | GB201411506D0 (enExample) |
| WO (1) | WO2015198072A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| CN115667523A (zh) * | 2020-04-10 | 2023-01-31 | 西托姆克斯治疗公司 | 可活化细胞因子构建体和相关组合物以及方法 |
| WO2022011434A1 (en) * | 2020-07-17 | 2022-01-20 | The University Of Western Australia | Compositions and methods for the treatment of cancer |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| CN120603603A (zh) * | 2023-01-12 | 2025-09-05 | 瑞泽恩制药公司 | 用于靶向递送TGFβ的组合物和方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US6942853B2 (en) * | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| AU2002243679A1 (en) * | 2001-01-24 | 2002-08-06 | Zymogenetics, Inc. | Cub domain protein zcub3 and materials and methods for making it |
| AU2006302587A1 (en) * | 2005-10-04 | 2007-04-19 | Greenville Hospital System | Latent procytotoxins and uses thereof |
| GB0724556D0 (en) | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| EP2377888A1 (en) * | 2010-04-07 | 2011-10-19 | Corimmun GmbH | Fusion protein |
-
2014
- 2014-06-27 GB GBGB1411506.7A patent/GB201411506D0/en not_active Ceased
-
2015
- 2015-06-26 JP JP2016574456A patent/JP6687548B2/ja not_active Expired - Fee Related
- 2015-06-26 WO PCT/GB2015/051877 patent/WO2015198072A1/en not_active Ceased
- 2015-06-26 EP EP15734226.2A patent/EP3160992B1/en active Active
- 2015-06-26 US US15/322,129 patent/US10435451B2/en not_active Expired - Fee Related
-
2019
- 2019-09-03 US US16/558,899 patent/US20200062814A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526625A5 (enExample) | ||
| WO2019002444A9 (en) | NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME | |
| PH12022550230A1 (en) | Antigen binding proteins specifically binding mage-a | |
| JP2014503198A5 (enExample) | ||
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| IL261432B1 (en) | Induced binding proteins and methods of use | |
| JP2012505902A5 (enExample) | ||
| JP2008511337A5 (enExample) | ||
| JP2016526909A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| WO2015188132A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| HRP20231118T1 (hr) | Sintetizirani polipeptidi koji vežu transferinske receptore | |
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2017501728A5 (enExample) | ||
| JP2014510518A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| WO2007126798A3 (en) | Regulated expression of recombinant proteins from adeno-associated viral vectors | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2018512124A5 (enExample) | ||
| JP2014510519A5 (enExample) | ||
| ATE517118T1 (de) | Bis-met-histone | |
| CN105658228B (zh) | 结合人类补体c5的稳定多肽 | |
| JP2010504336A5 (enExample) | ||
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof | |
| IL303152A (en) | Compositions and methods for selective depletion of target molecules |